ESSA Pharma Inc. (EPIX)

ESSA Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Net Income	-28.54	-28.54	-26.58	-35.1	-36.81	-23.45
Depreciation & Amortization	0.09	0.09	0.12	0.12	0.11	0.11
Loss (Gain) From Sale of Investments	-0.92	-0.92	-0.67	0.07	-	-
Stock-Based Compensation	6.54	6.54	5.01	7.89	9.48	7.52
Other Operating Activities	0.53	0.53	0.01	-0.2	-0.14	0.07
Change in Accounts Receivable	-0.03	-0.03	-0.13	0.48	-0.16	0.09
Change in Accounts Payable	-0.24	-0.24	1.24	-1.63	2.67	-0.05
Change in Income Taxes	-	-	-	-	-	-0.02
Change in Other Net Operating Assets	-0.15	-0.15	1.23	0.37	-0.56	-1.26
Operating Cash Flow	-22.72	-22.72	-19.78	-28	-25.42	-16.98
Investment in Securities	91.79	91.79	-3.53	-53.05	-35.03	-22.01
Other Investing Activities	-	-	-	-	0.01	0.27
Investing Cash Flow	91.79	91.79	-3.53	-53.05	-35.01	-21.74
Long-Term Debt Repaid	-	-	-0.14	-0.13	-0.1	-4.01
Net Debt Issued (Repaid)	-	-	-0.14	-0.13	-0.1	-4.01
Issuance of Common Stock	0.93	0.93	0.07	0.39	151.32	49.33
Other Financing Activities	-	-	-	-	-9.23	-3.54
Financing Cash Flow	0.93	0.93	-0.07	0.25	141.99	41.78
Foreign Exchange Rate Adjustments	0.01	0.01	0	0.05	-0.06	-0.06
Net Cash Flow	70.01	70.01	-23.37	-80.75	81.5	3
Free Cash Flow	-22.72	-22.72	-19.78	-28	-25.42	-16.98
Free Cash Flow Per Share	-0.51	-0.51	-0.45	-0.64	-0.66	-0.76
Cash Interest Paid	-	-	-	-	-	0.03
Levered Free Cash Flow	-15.2	-15.2	-12.62	-15.88	-11.68	-8.92
Unlevered Free Cash Flow	-15.2	-15.2	-12.62	-15.87	-11.67	-8.78
Change in Net Working Capital	0.32	0.32	-2.34	0.78	-1.96	1.71

Source: S&P Capital IQ. Standard template. Financial Sources.